Published in Lancet on August 21, 1976
Variability of colonic function in healthy subjects. Gut (1978) 1.82
Dietary fibre and colonic function. J R Soc Med (1978) 1.00
Water-holding by dietary fibre in vitro and its relationship to faecal output in man. Gut (1979) 0.95
Metabolic effects of dietary fiber. West J Med (1979) 0.77
[Dietary fibre: more than a matter of dietetics. I. Compounds, properties, physiological effects]. Wien Klin Wochenschr (2004) 0.77
Dietary fiber and disease. Bull N Y Acad Med (1982) 0.75
Comparison of the effect of drugs upon some commonly used measures of bowel transit time. Br J Clin Pharmacol (1978) 0.75
Food and fibre. Br Med J (1977) 0.75
Towards positive diagnosis of the irritable bowel. Br Med J (1978) 12.79
Coronary risk factors in people from the Indian subcontinent living in west London and their siblings in India. Lancet (1995) 5.79
Management of hyperlipidaemia: guidelines of the British Hyperlipidaemia Association. Postgrad Med J (1993) 4.28
LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. Nat Genet (2000) 3.73
Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett (1991) 3.10
Home monitoring of blood glucose using filter paper strips. Br Med J (1979) 2.86
Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med (2006) 2.55
Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis (1993) 2.48
Measurement of capillary blood glucose in filter-paper spots: an aid to the assessment of diabetic control. Br Med J (1978) 2.23
Omega 3 fatty acids for prevention and treatment of cardiovascular disease. Cochrane Database Syst Rev (2004) 2.05
Particle size of wheat, maize, and oat test meals: effects on plasma glucose and insulin responses and on the rate of starch digestion in vitro. Am J Clin Nutr (1988) 2.02
The response of human leucocyte cultures to stimulation by tuberculin and phytohaemagglutinin measured by the uptake of radioactive thymidine. Clin Exp Immunol (1967) 2.01
Prevention of macrovascular disease: absolute proof or absolute risk? Diabet Med (1995) 1.93
Plasma triglyceride and high density lipoprotein cholesterol as predictors of ischaemic heart disease in British men. The Caerphilly and Speedwell Collaborative Heart Disease Studies. Br Heart J (1992) 1.88
Acute metabolic response to human growth hormone in different types of dwarfism. Br Med J (1967) 1.86
Immunological aspects of premature ovarian failure associated with idiopathic Addison's disease. Lancet (1968) 1.83
Variability of colonic function in healthy subjects. Gut (1978) 1.82
Wheat fibre and irritable bowel syndrome. A controlled trial. Lancet (1977) 1.80
Outcome of case finding among relatives of patients with known heterozygous familial hypercholesterolaemia. BMJ (2000) 1.80
Corticosteroid-induced dwarfism in Still's disease treated with human growth hormone. Clinical and metabolic effects including hydroxyproline excretion in two cases. Ann Rheum Dis (1966) 1.78
Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk. J Med Genet (2006) 1.76
Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol (2001) 1.76
Survey on the use of pulmonary scintigraphy and angiography for suspected pulmonary thromboembolism in the UK. Clin Radiol (1991) 1.75
Estimated 10-year cardiovascular risk in a British population: results of a national screening project. Int J Clin Pract (2008) 1.75
Wrong lesson from Finnish trial of cardiovascular disease prevention. Lancet (1992) 1.74
Prevention of cardiovascular disease in systemic lupus erythematosus--proposed guidelines for risk factor management. Rheumatology (Oxford) (2003) 1.72
Home blood-glucose measurements without reflectance meter. Lancet (1980) 1.65
Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis (1991) 1.59
Acromegalic arthropathy. Ann Rheum Dis (1971) 1.56
Impact of migration on coronary heart disease risk factors: comparison of Gujaratis in Britain and their contemporaries in villages of origin in India. Atherosclerosis (2005) 1.55
Effects of insulin and glucose on very low density lipoprotein triglyceride secretion by cultured rat hepatocytes. J Clin Invest (1982) 1.53
Serum paraoxonase activity in patients with type 1 diabetes compared to healthy controls. Eur J Clin Invest (2002) 1.52
Colonscopy for investigation of unexplained rectal bleeding. Lancet (1978) 1.51
The effect on intestinal transit and the feces of raw and cooked bran in different doses. Am J Clin Nutr (1976) 1.50
HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis (1995) 1.48
Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol (1996) 1.48
Endothelial dysfunction in Type 1 diabetes mellitus: relationship with LDL oxidation and the effects of vitamin E. Diabet Med (1999) 1.46
Influence of proteinuria on vascular disease, blood pressure, and lipoproteins in insulin dependent diabetes mellitus. Br Med J (Clin Res Ed) (1987) 1.44
Iopamidol as contrast medium in endoscopic retrograde pancreatography: a prospective randomised comparison with diatrizoate. Endoscopy (1988) 1.43
Increased plasma-free-fatty-acid concentrations and their significance in patients with acute myocardial infarction. Lancet (1969) 1.43
Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol (1999) 1.42
Serum lipoprotein (a) in renal transplant recipients receiving cyclosporin monotherapy. Nephrol Dial Transplant (1993) 1.42
Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabet Med (2007) 1.42
Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett (1998) 1.40
Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol (1995) 1.40
Severe insulin resistance, diabetes mellitus, hypertriglyceridemia, and pseudoacromegaly. J Clin Endocrinol Metab (1996) 1.39
The effects of low-dose testosterone treatment on lipid metabolism, clotting factors and ultrasonographic ovarian morphology in women. Clin Endocrinol (Oxf) (1998) 1.38
Growing points. Hormones and the endocrine system. Br Med J (1966) 1.38
Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis (1998) 1.36
A radioimmunoassay for cholecystokinin-pancreozymin. Lancet (1973) 1.33
Lipoprotein (a): structure, properties and possible involvement in thrombogenesis and atherogenesis. Atherosclerosis (1990) 1.32
How trustworthy are bowel histories? Comparison of recalled and recorded information. Br Med J (1976) 1.29
Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br J Pharmacol (1997) 1.27
Nature of the transferable factor which causes abnormal platelet behaviour in vascular disease. Lancet (1967) 1.27
The importance of lipid-derived malondialdehyde in diabetes mellitus. Diabetologia (2000) 1.25
Effect of oral contraceptive agents on platelets and plasma-phospholipids. Lancet (1968) 1.23
Human serum paraoxonase. Gen Pharmacol (1998) 1.20
Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials. J Intern Med (2008) 1.20
Cortisol and growth hormone secretion in relation to linear growth: patients with Still's disease on different therapeutic regimens. Br Med J (1970) 1.20
Laboratory facilities for investigating lipid disorders in the United Kingdom: results of the British Hyperlipidaemia Association survey. J Clin Pathol (1992) 1.19
Cellular hypersensitivity to mitochondrial antigens in diabetes mellitus. Clin Exp Immunol (1973) 1.19
Increased immunolocalization of paraoxonase, clusterin, and apolipoprotein A-I in the human artery wall with the progression of atherosclerosis. Arterioscler Thromb Vasc Biol (1997) 1.18
Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia. Heart (2004) 1.17
The role of high-density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J (1993) 1.16
Human cholesterol metabolism and therapeutic molecules. Exp Physiol (2008) 1.15
Associations of alcohol consumption with plasma high density lipoprotein cholesterol and its major subfractions: the Caerphilly and Speedwell Collaborative Heart Disease Studies. J Epidemiol Community Health (1988) 1.13
Home blood glucose concentrations in maturity-onset diabetes. Br Med J (1980) 1.12
Clinical value of apolipoprotein measurement. Ann Clin Biochem (1991) 1.10
Changes in certain blood constituents during Ramadan. Am J Clin Nutr (1982) 1.09
How high-density lipoprotein protects against the effects of lipid peroxidation. Curr Opin Lipidol (2000) 1.08
Associations of the HDL2 and HDL3 cholesterol subfractions with the development of ischemic heart disease in British men. The Caerphilly and Speedwell Collaborative Heart Disease Studies. Circulation (1994) 1.07
Serum lipoprotein(a) in patients heterozygous for familial hypercholesterolemia, their relatives, and unrelated control populations. Arterioscler Thromb (1991) 1.07
Estimation of cholesterol in bile: assessment of an enzymatic method. Clin Chim Acta (1980) 1.06
Medical outpatients. J R Coll Physicians Lond (1988) 1.06
Radioimmunoassay of cholecystokinin-pancreozymin. Gut (1974) 1.06
Lipoprotein abnormalities in insulin-dependent diabetes mellitus. Lancet (1986) 1.04
Change of insulin dosage, circulating free and bound insulin and insulin antibodies on transferring diabetics from conventional to highly purified porcine insulin. Diabetologia (1978) 1.03
Apolipoproteins A-I, A-II and B, lipoprotein(a) and the risk of ischaemic heart disease: the Caerphilly study. Eur J Clin Invest (2000) 1.03
A simplified procedure for the analysis of cholesterol, phospholipids and bile salts in human bile. Clin Chim Acta (1978) 1.02
The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease. Atherosclerosis (2003) 1.01
Persistent fetal haemoglobin and falsely high glycosylated haemoglobin levels. Br Med J (Clin Res Ed) (1984) 1.01
Serum apolipoproteins AI and B and lipoproteins in middle aged men with and without previous myocardial infarction. Br Heart J (1986) 1.01
Alloenzymes of paraoxonase and effectiveness of high-density lipoproteins in protecting low-density lipoprotein against lipid peroxidation. Lancet (1997) 1.00
Aldehyde disinfectants and health in endoscopy units. British Society of Gastroenterology Endoscopy Committee. Gut (1993) 1.00
Coffee, blood pressure and plasma lipids: a randomized controlled trial. Eur J Clin Nutr (1989) 0.99
The use of yttrium 90 implantation in the treatment of acromegaly. Proc R Soc Med (1970) 0.98
Frequency of citation and outcome of cholesterol lowering trials. BMJ (1992) 0.98
Low paraoxonase activity in type II diabetes mellitus complicated by retinopathy. Clin Sci (Lond) (2000) 0.98
Omega-3 fatty acids: their role in the prevention and treatment of atherosclerosis related risk factors and complications. Int J Clin Pract (2003) 0.98
A cross-sectional evaluation of cardiovascular risk factors in coronary heart disease associated with type 1 (insulin-dependent) diabetes mellitus. Diabetes Res Clin Pract (1992) 0.97
The immediate effect of streptokinase on serum lipoprotein(a) concentration and the effect of myocardial infarction on serum lipoprotein(a), apolipoproteins A1 and B, lipids and C-reactive protein. Atherosclerosis (1993) 0.96
Is paraoxonase related to atherosclerosis. Chem Biol Interact (1993) 0.96
Hypertriglyceridemia and hyperuricemia: effects of two fibric acid derivatives (bezafibrate and fenofibrate) in a double-blind, placebo-controlled trial. Metabolism (1988) 0.96
Polymorphisms of paraoxonase genes and low-density lipoprotein lipid peroxidation. Lancet (1999) 0.95
Preparation of the large bowel for endoscopy. J Int Med Res (1977) 0.94
Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin(1). Diabet Med (2011) 0.94
Hydrolysis of platelet-activating factor by human serum paraoxonase. Biochem J (2001) 0.94
Alcohol consumption and its relation to cardiovascular risk factors in British women. BMJ (1992) 0.94
The prevalence of hyperlipidaemia and related clinical features in insulin-dependent diabetes mellitus. Q J Med (1989) 0.94